Inspire ophthalmic, pulmonary news
Inspire will restructure and reduce headcount by 20 (8%) to 230, with cuts in preclinical research to focus on late stage clinical and marketed programs. The company's marketed products include AzaSite for bacterial conjunctivitis, Elestat epinastine for allergic conjunctivitis and Restasis cyclosporine for dry eye. Inspire has North American rights to AzaSite from InSite Vision Inc. (NYSE-A:ISV, Alameda, Calif.), and co-promotes Elestat and Restasis with Allergan Inc. (NYSE:AGN, Irvine, Calif.). Inspire's pipeline includes Phase III compounds: Prolacria diquafosol tetrasodium ( INS365), a uridine 5'-triphosphate (UTP) natural P2Y2 ligand to treat dry eye; and INS37217 denufosol tetrasodium, a second-generation P2Y(2) receptor agonist to treat cystic fibrosis (CF). Prolacria is partnered with Allergan. ...